肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Imbruvica和Gazyvo联用获FDA批准用于治疗慢性淋巴细胞白血病

2019-01-28 MedSci MedSci原创

Imbruvica慢性淋巴细胞白血病Gazyvo
关注

重镑白血病药物Imbruvica再次扩大其应用范围，近日获得FDA批准与Gazyvo联合用于慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL / SLL）的一线治疗。

重镑白血病药物Imbruvica再次扩大其应用范围，获得FDA批准与Gazyvo联合用于慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL / SLL）的一线治疗。

此次FDA的批准是针对CLL / SLL患者的首次非化疗联合治疗方案，这次的批准也代表着Imbruvica自2013年11月美国推出以来第10次被批准新适应症。

临床研究显示，在中位随访31个月后，Imbruvica加obinutuzumab联用，与苯丁酸氮芥和obinutuzumab联用相比，无进展生存期显着改善，进展或死亡风险降低了77％。

该组合治疗的高风险患者（17p缺失/ TP53突变，11q缺失，或IGHV未突变），进展或死亡风险降低了85％。

这些结果都提示Imbruvica可能其他类型患者中也有很好的疗效，包括非老年人群和化学免疫疗法候选患者。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1714812, encodeId=a2941e1481203, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Apr 01 07:24:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997933, encodeId=3a57199e93338, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Fri Oct 11 04:24:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839650, encodeId=9b981839650b5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 28 12:24:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302229, encodeId=e5a913022291c, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Jan 30 12:24:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312497, encodeId=2a9e131249eff, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9752, encryptionId=dc0c9e5231, topicName=Imbruvica)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Jan 30 12:24:00 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2019-04-01 仁心济世

    #AZ#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1714812, encodeId=a2941e1481203, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Apr 01 07:24:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997933, encodeId=3a57199e93338, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Fri Oct 11 04:24:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839650, encodeId=9b981839650b5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 28 12:24:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302229, encodeId=e5a913022291c, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Jan 30 12:24:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312497, encodeId=2a9e131249eff, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9752, encryptionId=dc0c9e5231, topicName=Imbruvica)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Jan 30 12:24:00 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2019-10-11 sunyl07

    #淋巴细胞白血病#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1714812, encodeId=a2941e1481203, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Apr 01 07:24:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997933, encodeId=3a57199e93338, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Fri Oct 11 04:24:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839650, encodeId=9b981839650b5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 28 12:24:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302229, encodeId=e5a913022291c, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Jan 30 12:24:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312497, encodeId=2a9e131249eff, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9752, encryptionId=dc0c9e5231, topicName=Imbruvica)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Jan 30 12:24:00 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2019-06-28 智者为医08

    #FDA批准#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1714812, encodeId=a2941e1481203, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Apr 01 07:24:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997933, encodeId=3a57199e93338, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Fri Oct 11 04:24:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839650, encodeId=9b981839650b5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 28 12:24:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302229, encodeId=e5a913022291c, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Jan 30 12:24:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312497, encodeId=2a9e131249eff, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9752, encryptionId=dc0c9e5231, topicName=Imbruvica)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Jan 30 12:24:00 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2019-01-30 wetgdt

    #淋巴细胞#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1714812, encodeId=a2941e1481203, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Apr 01 07:24:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997933, encodeId=3a57199e93338, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Fri Oct 11 04:24:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839650, encodeId=9b981839650b5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jun 28 12:24:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302229, encodeId=e5a913022291c, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Jan 30 12:24:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312497, encodeId=2a9e131249eff, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9752, encryptionId=dc0c9e5231, topicName=Imbruvica)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Jan 30 12:24:00 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2019-01-30 syscxl

    #Imbruvica#

    0

相关资讯

5个适应证！FDA批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）

2016年3月9日/生物谷BIOON/--美国生物技术巨头艾伯维（AbbVie）抗癌管线近日在美国监管方面传来特大喜讯，FDA已批准突破性抗癌药Imbruvica（ibrutinib）用于慢性淋巴细胞白血病（CLL）患者的一线治疗。此次批准，首次为CLL群体提供了一种无化疗（chemotherapy-free）的一线治疗选择，同时也使得Imbruvica在美国的治疗适应症达到了5个之多。此前，

Janssen的Imbruvica最终被纳入NHS

Janssen的Imbruvica将被纳入NHS，用于某些患有套细胞淋巴瘤（MCL）患者的常规治疗，此前成本监管机构已经为该药发布了最后的绿灯。在最后的指导方针中，英国国家医疗服务体系批准Imbruvica（ibrutinib）用于治疗只有这一种选择的患者。该机构之前表示，它不能为整个MCL患者群推荐该药，因为它没有提供NHS的资金价值，但是在二级保健中，Imbruvica可以被认为处于"临终"阈

6个适应症！FDA批准艾伯维突破性药物Imbruvica治疗小淋巴细胞性淋巴瘤（SLL）

美国制药巨头艾伯维（AbbVie）近日宣布，美国食品和药物管理局（FDA）已更新突破性抗癌药Imbruvica（ibrutinib）的处方信息（Prescribing Information，PI），纳入2项III期临床研究的新数据，这些研究支持了Imbruvica扩大应用于慢性淋巴细胞白血病（CLL）和小淋巴细胞性淋巴瘤（SLL）的治疗。 此次标签更新纳入了Imbruvica一线治疗CLL

强生突破性抗癌药Imbruvica第4个适应症获欧盟CHMP支持

医疗巨头强生（JNJ）近日在欧盟监管方面收获喜讯，该公司与合作伙伴Pharmacyclics合作研发的突破性抗癌药物Imbruvica（ibrutinib）获得了欧洲药品管理局（EMA）人用医药产品委员会（CHMP）的积极意见。CHMP支持批准Imbruvica的新适应症，用于既往已接受过至少一次治疗的Waldenstrom巨球蛋白血症（WM）成人患者，或不适合化学-免疫疗法的WM成人患者的一

第5个适应症！欧盟批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）

由艾伯维（AbbVie）和强生（JNJ）合作开发的一款突破性抗癌药Imbruvica（ibrutinib）近日在欧盟监管方面传来喜讯，欧盟委员会（EC）已批准Imbruvica用于慢性淋巴细胞白血病（CLL）成人患者的一线治疗。此次批准，是Imbruvica在欧洲市场收获的第5个适应症。而在美国市场，FDA在今年3月4日已批准Imbruvica一线治疗CLL成人患者，这也是Imbruvica在

强生抗癌药Imbruvica新适应症获FDA批准

强生（JNJ）和Pharmacyclics公司2月12日宣布，抗癌药Imbruvica（ibrutinib胶囊）获FDA批准，用于既往接受过至少一次治疗的慢性淋巴细胞白血病（CLL）患者的治疗。Imbruvica已于2013年11月获FDA批准，用于既往接受过至少一次来那度胺或其他药物治疗的套细胞淋巴瘤（MCL）患者的治疗。这2个适应症的获批，均基于整体缓解率（ORR）数据，该药对存活或疾病相关症